definiens: means any Technology made, developed or conceived by employees or consultants of AstraZenec a, alone or jointly with Third Parties, in the cond uct of : ( a ) the [COMPANY] Research Activities, but in eac h case only if not [COMPANY] Assigned Technology ; or ( b ) any Clinical Trial of a Basket Compound conduct ed in whole or in part after the Amendment No . 5 Da te, but, solely in the case this clause ( b ), where such Tech nology constitutes a method of use or treatment ( or otherwise constitutes a new therapeutic use ), or pharmaceutic al composition, of or for such Basket Compound . For purposes of clarity, ( i ) Technology with respect to Ispronicline made, developed or conceived by emplo yees or consultants of [COMPANY], alone or jointly with T hird Parties, shall not be [COMPANY] Research Pro gram Technology and ( ii ) Technology that is [COMPANY] Research Program Technology pursuant to clause ( b ) above shall also be [COMPANY] Development Program Techn ology . ” 4 . The Agreement is hereby amended by adding the fo llowing new Section 1.52A : means each of AZD1446 ( TC-6683 ), [ * * * ], in each ca se identified by the chemical structure acknowledged by the Parties as such compound as of the Amendment No . 5 Date, an y enantiomer, metabolite or Prodrug of any of the afo rementioned compounds, and, in each case, any salt form, polymorph, crystalline form, hydrate, solvate or fo rmulation thereof . ” 5 . Section 1.62 of the Agreement is hereby deleted in its entirety and replaced with the following : means the alliance of [COMPANY] and [COMPANY] es tablished pursuant to this Agreement . ” 6 . Section 1.76 of the Agreement is hereby deleted in its entirety and replaced with the following : means any research, development or commercializat ion activity of a Third Party that involves an Alpha4Beta2 Agonist or a product that contains an Alpha4Beta2 Agonist as an active ingredient for use in the Field or, prior to the Schizophrenia Expiration Date, Schizophrenia t hat would ( a ) were such Third Party to undergo a Change of Co ntrol transaction with [COMPANY], cause [COMPANY] t o be in breach of any of its exclusivity obligations under Section 8.6.1, or ( b ) were such Third Party to unde rgo a Change of Portions of this Exhibit, indicated by the mark were omitted and have been filed separately w ith the Securities and Exchange Commission pursuant to the Registrant ’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended